JPMorgan Chase & Co. Has $10.10 Million Stake in Annexon, Inc. (NASDAQ:ANNX)

JPMorgan Chase & Co. increased its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 16.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,706,182 shares of the company’s stock after buying an additional 235,810 shares during the period. JPMorgan Chase & Co. owned 1.60% of Annexon worth $10,101,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Sandia Investment Management LP bought a new position in shares of Annexon during the 2nd quarter worth about $49,000. Victory Capital Management Inc. acquired a new stake in shares of Annexon during the second quarter worth approximately $51,000. Principal Financial Group Inc. bought a new position in Annexon in the 2nd quarter valued at $56,000. Quarry LP bought a new stake in Annexon during the 3rd quarter worth about $118,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Annexon in the third quarter valued at approximately $154,000.

Insider Activity at Annexon

In related news, EVP Ted Yednock sold 5,408 shares of Annexon stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total transaction of $40,073.28. Following the completion of the transaction, the executive vice president now owns 71,365 shares in the company, valued at approximately $528,814.65. This trade represents a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.67% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on ANNX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Annexon Trading Down 0.2 %

Shares of ANNX opened at $4.83 on Monday. The firm has a fifty day simple moving average of $5.47 and a 200 day simple moving average of $5.95. Annexon, Inc. has a 12 month low of $3.86 and a 12 month high of $8.40. The stock has a market capitalization of $514.85 million, a price-to-earnings ratio of -4.60 and a beta of 1.11.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.